ReviewNeuropsychopharmacology reports2024
Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspective.
Review in Neuropsychopharmacology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Structure-Dependent Cytotoxic and Cytoprotective Effects of Molybdenum(VI) Schiff Base Complexes in the Neuronal Cells In Vitro.Molecules (Basel, Switzerland) · 2026Article
- Protective Effect of Uric Acid on Rat Model of Irritable Bowel Syndrome Requires Brain-Gut Communication Through Vagal Cholinergic Pathways.Neurogastroenterology and motility · 2026Article
- Targeting inflammaging in Alzheimer's disease: molecular pathways and emerging pharmacotherapies.Inflammopharmacology · 2026Review
- Association between serum non-enzymatic antioxidants and cognitive impairment in drug-naïve patients with schizophrenia.BMC psychiatry · 2026Article
- The study on cerebral variations and cognitive function in male patients with hyperuricemia using amide proton transfer imaging.Quantitative imaging in medicine and surgery · 2026Article
- Toxicological effects of volatile organic compounds are mediated by aggravated oxidative stress and neuroinflammatory processes in piglets.Toxicology reports · 2026Article
- Repurposing of doxycycline as a novel therapeutic avenue for management of parkinson's disease.Inflammopharmacology · 2026Review
- Enzymatic Bioautographic Methods.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Albiflorin-Mediated MAP2K1 Targeting and HIF-1 Signaling Inhibition Contribute to the Therapeutic Efficacy in Hyperuricemia-Associated Cognitive Impairment.Human mutation · 2026Article
- Allopurinol Reprograms Uric Acid Self-Assembly by Disrupting Cytotoxic Fibrils and Redirecting Crystal Growth.JACS Au · 2025Article
- Development of a multidimensional machine learning framework for predicting post-stroke cognitive impairment: A prospective cohort study.Clinical and translational medicine · 2025Article
- "Rewiring brain immunity: targeting microglial metabolism for neuroprotection in neurodegenerative disorders".Metabolic brain disease · 2025Review
- Targeting of the PI3 K/AKT/GSK3β Pathway in Parkinson's Disease: A Therapeutic Blueprint.Molecular neurobiology · 2025Review
- Tirzepatide: a novel therapeutic approach for Alzheimer's disease.Metabolic brain disease · 2025Review
- Review
- Unraveling the Immune Puzzle: Role of Immunomodulation in Alzheimer's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Review
- Early Detection and Management of Cognitive Impairment in Parkinson's Disease: A Predictive Model Approach.Brain and behavior · 2025Article
- Hyperuricemia reduces the risk of MCI but not dementia: a cross-sectional study in Liuyang.Frontiers in neurology · 2025Article
- Hyperuricaemia is associated with smaller volumes in the caudate nucleus head and putamen.Brain communications · 2025Article
- Molecular and Clinical Perspectives on the Regulation of Sleep and Uric Acid Metabolism.Nature and science of sleep · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neurodegenerative diseases (NDs) such as Alzheimer disease (AD) and Parkinson disease (PD) are group of diseases affecting the central nervous system (CNS) characterized by progressive neurodegenerations and cognitive impairment. Findings from different studies highlighted the beneficial and detrimental effects of serum uric acid on the development and progression of NDs. Therefore, this mini-review aims to discuss the beneficial and detrimental effects of uric on NDs. The neuroprotective effect of uric acid is mainly related to the antioxidant effect of uric acid which alleviates oxidative stress-induced neurodegeneration in AD and PD. However, long-term effect of hyperuricemia prompts for the development and progression of cognitive impairment. Hyperuricemia is associated with cognitive impairment and dementia, and gout increases dementia risk. In addition, hyperuricemia can cause cerebral vascular injury which is a risk factor for vascular dementia and cognitive impairment. Taken together, the relationship between uric acid and NDs risk remains conflicting. Hence, preclinical and clinical studies are indicated in this regard.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.